Advanced approaches of ocular drug delivery system
DOI:
https://doi.org/10.56511/JIPBS.2016.v3.i04.pp148-156Abstract
Eye is the most select organ of the body and different medication conveyance frameworks are utilized to convey tranquilize into eye yet there are different impediments like fast precorneal sedate loss of customary frameworks. Visual attitude and disposal of a helpful operator is reliant upon physicochemical, microbiological, pharmaceutical properties and ophthalmic irritancy properties of visual measurement shapes and also the significant visual life structures and physiology. To enhance visual medication contact time, bioavailability and home time, and to decrease the patient distress, recurrence of measurements, and additionally to back off the end of the medication there are critical endeavours concentrating towards more up to date tranquilize conveyance frameworks for ophthalmic organization. This audit concentrates on the different new medication conveyance frameworks connected in eye like supplements, in-situ gel, the recently created particulate and vesicular frameworks like liposome, pharmacosomes and discomes, niosomes, nanoparticles, iontophorosis, corneal shields, tranquilize installed contact focal points, visual wafers and so on and the latest progressed methodologies of the occular drug delivery like the conveyance of the qualities and proteins to the inside structures which were utilized as a part of treating the sicknesses brought on because of hereditary transformation, alongside security assessment of ocular medication conveyance details with some contextual investigations.
Keywords:
Ophthalmic Irritancy, advanced ocular therapy, Ocular Drug Deliver, safety evaluationDownloads
References
K. S. G. Arul Kumaran, K. Karthika and J. Padmapreetha: Comparative review on conventional and advanced ocular drug delivery. International Journal of Pharmacy and Pharmaceutical Sciences 2010; 2(4): 1-5.
S. W. Jacob and C. A. Francone: structure and function in man; 2nd edition, W. B. Sauder, Philadelphia, 1970, Chapter 17.
K. P. Sampath Kumar, Debjit Bhowmik, G. Harish, S. Duraivel, B. Pragathi kumar: Ocular Inserts: A Novel Controlled Drug Delivery System. The pharma innovation journal 2013; 1(12): 1-16.
Wolff, E: Anatomy of eye and orbit. Blakistone Company, New York and Toronto, 4th edition, 1954:207.
Stella, V.J; Mikkelson, T.J; Pipkin, J.D: Drug Delivery System: Characterictic and Biomedical application. Oxford university press; New York; 1996; 5th edition 112.
Brian GS: Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations, Toxicologic pathology 2008; 36:49-62.
Mitra AK: Fundamentals of ocular drug delivery. American Association of Pharmaceutical Scientists Journal 2010; 12(3):348-360.
Barar et al. Ocular novel drug delivery, impacts of membranes and barriers. Expert Opin Drug Deliv 2008; 5(5):567-8.
Kim et al.: Fundamentals of ocular drug delivery. Ophthalmic Res. 2007; 39:244-54.
Wadhwa S, Paliwal R, Paliwal SR, Vyas SP.: Nanocarriers in ocular drug delivery: Current Pharmaceutical Design 2009; 15: 2724-2750.
Mueller WH, Deardroff DL: Ophthalmic vehicles: The effect of methyl cellulose on the penetration of Homatropine hydro bromide through the cornea. American Association of Pharmaceutical Scientists Journal 1956; 334-341.
Maichuk YF: Ophthalmic drug inserts. Invest Ophthalmol 1975; 87 – 90.
MF Seattone: Solid polymeric inserts/disks as drug delivery devices. In: P Edman, ed. Biopharmaceutics of Ocular Drug Delivery. Boca Raton, FL: CRC Press 1993; 61 – 79.
Kaur IP, Garg A, Singla AK, Agarwal D: Vesicular systems in ocular drug delivery. International Journal of Pharmaceutical 2004; 269:1-14.
Vyas SP, Mysore N, Jaitely V, Venkatesan N: Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 1998; 53(7): 466-469.
Guinedi AS, Mortada ND, Mansour S, Hathout RM: Preparation and evaluation ofreverse-phase evaporation and multilamellarniosomes as ophthalmic carriers of acetazolamide. American association of pharmaceutical scientists journal 2005; 306:71-82.
Kaur IP, Kanwar M: Ocular preparations: The formulation approach. Drug developmentIndrustrial Pharmacy 2002; 28(5):473-493.
VHL Lee, JR Robinson. Review: Topical drug delivery: recent developments and future challenges. Journal Oculus Pharmacol. 1986; 2:67 – 108.
Saettone MF, Bucci G, Speiser P: Ophthalmic Drugs Delivery: Biopharmaceutical, Technological, Clinical Aspects. Fidia Research Series, Padova, Italia: Latvian Press 1987; 11.
VHL Lee: New directions in the optimization of ocular drug delivery. Journal ofOculPharmacol 1990; 6:157 – 164.
Edman P: Biopharmaceutics of Ocular Drug Delivery. Boca Raton, FL: CRC Press 1993.
AK Mithra: Ophthalmic Drug Delivery Systems. New York: Marcel Dekker 1993.
M Van Ooteghem: Preparations Ophtalmiques, Paris: Technique & Documentation 1995.
Frangie JP: Clinical pharmacokinetics of various topical ophthalmic delivery systems. Clin Pharmacokinetic 1995; 29:130 – 138.
Kimura H, Ogura Y, HashizoeM, Nishiwaki H, Honda Y, Ikad Y: A new vitreal drug delivery system using an implantable biodegradable polymeric device. Investigative Ophthalmology & Visual Science 1994; 35:2815-2819.
Hill JM, O’Callaghan RJ, Hobden JA: Ocular Iontophoresis. In: Mitra AK. Ophthalmic Drug Delivery Systems. New York: M. Dekker Inc; 1993; 331-354.
Rootman DS, Janssen JA, Gonzalez JR, Fischer MJ, Beuerman R, Hill JM: Pharmacokinetics and safety of transcorneal iontophoresis of tobramycin in the rabbit. Investigative Ophthalmology & Visual Science 1988; 29:1397-1401.
Callahan MC, Hobden JA, O’Callaghan RJ, Hill JM: Ocular drug delivery, A comparison of transcorneal iontophoresis to corneal collagen shields. International Journal of Dharma 1995; 123:173179.
Usayapant A, Karri AH, Narurkar MM: Effect of 2-hydroxypropyl-betacyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharmaceutical Research 1991; 8: 1495 – 1499.
Vainer M, Amidon G, Lindenbaum S, Haslam JL: Thermodynamic studies on the gelsol transition of some pluronic polyols. International Journal of Pharmaceutical 1984; 22: 207-218.
Vasantha R, Sehgal PK, Rao P: Collagen ophthalmic inserts for Pilocarpine drug delivery system. International Journal of Pharmaceutical, 1988; 47: 95-102.
Patravale VB, Date AA, Kulkarni RM.: Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004; 56: 827-840.
Jiang J, Gill HS, Ghate D, McCarey BE, Patel SR, Edelhauser HF, Prausnitz MR.: Coated microneedles for drug delivery to the eye. Investigative Ophthalmology & Visual Science 2007; 48:4038 – 4043.
Green K, Chapman JM, Cheeks L, Clayton RM, Wilson M, Zehir A: Detergent penetration into young and adult rabbit eyes: comparative pharmacokinetics. Journal of Toxicology Cutaneous And Ocular Toxicology 1987; 6:89 – 107.
Ch’ng HS, Park H, Kelly P, Robinson JR: For oral controlled delivery II: Synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. Journal of Pharmaceutical Science 1985; 74:399-405.
Middleton DL, Robinson JR. Design and evaluation of an ocular bio adhesive delivery system. S.T.P. Pharma Sci 1991;1:200-206.
Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P: PGLA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: In vitro/in vivo studies. Europen Journal of Pharmaceutical and Biopharmaceutical 2004; 57: 207 – 212.
Yasukawa T, Kimura H, Tabata Y, Ogura Y: Biodegradable scleral plugs for vitreoretinaldrug delivery. Advanced Drug Delivery Reviews 2001; 52(1): 25-36.
Selvam S, Thomas PB, Hamm-Alvarez SF, Schechter JE, Stevenson D, Mircheff AK, Trousdale MD: Current status of gene delivery and gene therapy in lacrimal gland using viral vectors. Advance drug delivery Research 2006; 58:1243 – 1257.
Klausner EA, Peer D, Chapman RL, Multack RF, Andurkar SV: Corneal gene therapy. Journal of Control Release 2007; 124: 107 – 133.
Campochiaro PA: Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Therapy 2006; 13:559 – 562.
Levin LA, Ritch R, Richards JE, Borras T.: Stemcell therapy for ocular disorders. Arch Ophthalmol 2004; 122(4): 621-627.
Tao W.: Application of encapsulated cell technology for retinal degenerative diseases. Expert Opinion on Biological Therapy 2006; 6: 717 – 7
Published
How to Cite
Issue
Section
Copyright (c) 2016 Syeda Amena, Shireen Begum, Nazima Sultana, Syed Aamir Sohail, Syed Aziz Uddin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at